UCL Institute of Child Health, London
24th April 2009
Talks Include:
How to make a new antibody work for IHC?' And that is what most of us want, isn't it? Dr Chris van der Loos, Academic Medical Center, Amsterdam, The Netherlands Every day, newly developed antibodies are becoming commercially available. Because the majority of new antibodies are not primarily designed for IHC application, datasheets are not informative. Often lacking are relevant notes if the antibody is tested for IHC (cryo or paraffin), positive control tissue, optimal antigen retrieval method, and description of the expected IHC tissue staining pattern. A number of generally applicable approaches and tools are presented for exploring the IHC staining potential of newly developed antibodies. Also, a generally applicable double staining method is discussed and suggestions are made how to make a positive/negative control block from cells.
FISH techniques and applications
Dr Paul A.W. Edwards, Reader in Cancer Biology, Department of Pathology, University of Cambridge.
FISH techniques will be reviewed with reference both to recent developments and to current well-established applications
Patient Safety in the Pathology Environment
Mr Chris Rhoades, Dako UK Ltd, Cambridgeshire, UK
Immunohistochemical Investigation of Lynch / HNPCC syndrom
Dr Mark Arends, University Reader & Hon Consultant University of Cambridge & Addenbrooke’s Hospital, Cambridge, UK
Hereditary non-polyposis colorectal cancer (HNPCC) or Lynch syndrome accounts for 2-4% of colorectal cancers and is caused by inheritance of a mutated Mismatch Repair gene, usually MSH2 or MLH1, but occasionally others (e.g. MSH6 or PMS2). This leads to microsatellite instability (MSI) in tumour DNA. Extra-colonic tumours may also develop such as those of endometrium, ureter, ovary, stomach, small intestine, and skin (sebaceous tumours). Suspected HNPCC cases are identified by family history and their tumours examined for abnormal MMR protein expression by immunohistochemistry for MLH1, MSH2, MSH6 and PMS2, with different expression patterns for normal (homogeneously positive) and MMR abnormal (homogeneously or weakly negative) tumours.
PathGrid: the application of astronomical image analysis and data access techniques to the study of histopathology data.
Dr Nicholas Walton of the Institute of Astronomy
Dual fluorescence methods for wholemount and sections
Carrie Ambler, UK
Preparation and uses of frozen tissue microarrays.
Helen Shulver, Asterland UK
|
|